Aug. 21 at 1:19 PM
$SVRA
(+) NEJM Publication and Glowing Editorial on Molbreevi's Phase III aPAP Study An NEJM publication reinforces (+) efficacy findings from Molbreevi's 48-week Phase III IMPALA-2 (N=164): (1) The Week 24 primary endpoint of Hgb-adjusted DLCO showed a +6.0% pbo-adj benefit (p<0.001), which remained durable. (2) We know 6/81 Molbreevi patients (7%) underwent a total of 15 whole lung lavages (WLLs), whereas 11/83 placebo patients (13%) underwent 24 WLLs. Reducing the need for invasive WLL should have (+) implications for payor access, positioning Molbreevi as a 1L therapy. (3) Add'l outcomes data suggest Molbreevi decreases surfactant burden (GGO) and benefits quality-of-life (SGRQ-T, SGRQ-A). Editorial reads quite positive as well, characterizing IMPALA-2's success as an advancement and "an important step forward" that should "establish [Molbreevi] as the standard of care" in aPAP--A TSAI JEFFERIERS
